News & Updates

Response to first-line treatment tied to longer survival in HER2-positive breast cancer
Response to first-line treatment tied to longer survival in HER2-positive breast cancer
30 Mar 2024

Patients with de novo human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC) who show radiographic response to first-line HER2-directed therapy are more likely to achieve long-term survival, suggests a recent study.

Response to first-line treatment tied to longer survival in HER2-positive breast cancer
30 Mar 2024
SBRT as effective as Y90 for HCC, but cheaper
SBRT as effective as Y90 for HCC, but cheaper
29 Mar 2024

Use of either stereotactic body radiotherapy (SBRT) or yttrium-90 (Y90) is effective in the management of hepatocellular carcinoma (HCC), resulting in similar overall and progression-free survival, reports a study. However, Y90 is more expensive than SBRT.

SBRT as effective as Y90 for HCC, but cheaper
29 Mar 2024